抗糖尿病药物瑞格列奈的合成  

Synthesis of Antidiabetic Medicine Repaglinide

作　　者：赵爽[1] 徐志炳[1] 鄂晨光[1] 李卓[1] 王恩思[1] 

机构地区：[1]吉林大学生命科学学院,长春130021

出　　处：《吉林大学学报（理学版）》2008年第3期556-559,共4页Journal of Jilin University:Science Edition

基　　金：吉林省科技厅基础研究项目基金(批准号:20030550-4)

摘　　要：以4-甲基水杨酸、2-氯苯腈为原料,采用LDA/DMPU催化羧基化和Ph3P催化缩合反应为关键步骤合成瑞格列奈,总收率为10.5%.该合成方法具有工艺路线短、总收率高、操作简单等优点,适合工业化生产.其中关键中间体及瑞格列奈的结构用元素分析、红外光谱、核磁共振氢谱及碳谱、质谱和比旋光等方法表征.Repaglinide （ a new antidiabetic medicine ）, （ S ） - （ ＋ ） -2-ethoxy-4- [ N- [ 1 - （ 2-piperidinophenyl ） - 3-methyl-1-butyl] aminocarbonylmethy1] benzoic acid, was synthesized by means of Ph3P catalyzed condensation and LDA/DMPU catalyzed carboxylation as pivotal steps from the starting materials 4-methylsalicylic acid and 2-chlorobenzonitrile. Repaglinide was synthesized in a total yield of 10.5%. The structures of the target molecule and the key intermediates were confirmed by IR, ^1H NMR, ^13C NMR, elemental analysis, specific rotation and MS techniques.

关 键 词：瑞格列奈 化学拆分 旋光性 抗糖尿病药物 

分 类 号：R977.15[医药卫生—药品]